The rapid expansion of ketamine and esketamine (Spravato) infusion clinics for treatment-resistant depression has created a new category of behavioral health practice with a highly specialized administrative profile. Unlike standard outpatient psychiatry, infusion clinics operate under FDA Risk Evaluation and Mitigation Strategy (REMS) requirements, must document Abnormal Involuntary Movement Scale (AIMS) assessments for long-term patient monitoring, navigate a complex and variable insurance prior authorization landscape for esketamine, and collect structured outcomes data to demonstrate treatment effectiveness. Managing all of this alongside the clinical demands of in-office infusion monitoring requires dedicated administrative support — and virtual assistants are increasingly filling that role.
REMS Enrollment and Monitoring Documentation
Janssen's Spravato REMS program requires that every prescribing clinician, dispensing pharmacy, and healthcare setting administering esketamine be enrolled in the REMS program and maintain enrollment documentation. Clinics must also document patient enrollment in the REMS program and attest that required patient monitoring (minimum two hours of in-office observation post-administration) has occurred for every session.
The FDA's MedWatch REMS reporting system requires periodic re-attestation and enrollment renewal, and clinics that fail to maintain REMS compliance risk losing their ability to prescribe and administer Spravato. For a clinic running 10 to 30 Spravato sessions per week, maintaining REMS documentation for every session — patient consent, monitoring attestation, adverse event reporting — is a significant ongoing administrative task.
According to the American Society of Ketamine Physicians, Psychotherapists & Practitioners (ASKP3), REMS documentation compliance is the administrative function most frequently cited as a pain point by Spravato clinic operators. Virtual assistants manage the REMS documentation workflow: completing per-session attestation records, tracking enrollment renewal timelines, preparing adverse event reports when required, and maintaining an audit-ready REMS compliance file for each patient.
AIMS Tracking for Long-Term Monitoring
The Abnormal Involuntary Movement Scale is used in psychiatric practice to monitor for tardive dyskinesia and other movement side effects in patients receiving antipsychotics — but in ketamine and Spravato practices, AIMS assessments are used as part of broader long-term safety monitoring protocols. For clinics treating patients over months or years, maintaining systematic AIMS tracking intervals and ensuring that assessments are completed on schedule requires active monitoring.
Virtual assistants maintain AIMS tracking schedules for each patient, send reminders to clinical staff when AIMS assessments are due, log completed assessment scores in the patient record, and flag any scores that show significant change for clinical review. This systematic monitoring approach demonstrates clinical diligence and supports the long-term safety documentation that payers and regulators increasingly expect from infusion clinics.
Infusion Session Scheduling and Insurance Prior Authorization
Insurance coverage for Spravato (esketamine) has expanded significantly since FDA approval, with Medicare and many commercial payers now covering esketamine for treatment-resistant depression when prior authorization criteria are met. However, the prior authorization process varies substantially by payer and often requires documentation of adequate trials of multiple antidepressant medications, psychiatrist documentation of treatment-resistant depression diagnosis, and session-by-session authorization renewal.
Virtual assistants manage the prior authorization lifecycle for esketamine: gathering required clinical documentation from the psychiatrist, preparing authorization requests to payer specifications, tracking approval status, requesting authorization renewals as existing approvals expire, and escalating denials for peer-to-peer review. For clinics where esketamine sessions represent a significant portion of revenue, systematic prior authorization management is a direct financial function.
Outcomes Data Collection
Ketamine and Spravato clinics that want to demonstrate treatment effectiveness to payers, referral sources, and patients must collect structured outcomes data — standardized depression scales (PHQ-9, MADRS), functional assessment scores, and adverse event tracking. Collecting this data systematically at each session requires patient engagement and administrative follow-through.
Virtual assistants send outcomes assessment questionnaires to patients before each session, track completion, enter scores into the outcomes tracking system, and generate aggregate outcomes reports. This data infrastructure supports payer negotiations, quality reporting, and the practice's clinical reputation. Clinics building out their administrative support can explore virtual assistant services through Stealth Agents.
Sources
- U.S. Food and Drug Administration. "Spravato REMS Program Requirements." fda.gov
- American Society of Ketamine Physicians, Psychotherapists & Practitioners. "Practice Management Survey: Spravato Clinic Operations." askp3.org
- Janssen Pharmaceuticals. "Spravato REMS Healthcare Setting Enrollment Guide." spravatorems.com